Foscenvivint for Liver Cirrhosis in People With Hemophilia and HIV and Hepatitis C
Tests foscenvivint in adults with cirrhosis from HIV and hepatitis C with hemophilia.
Plain-language title generated from the registry record
Registry title: A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia
Key facts
- Where
- Bunkyo Ku, Osaka, Sapporo, and Sendai, JapanSee the 4 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 79 years old?
Source: NCT07681089, who can take part
Where in Japan
- Tokyo Metropolitan Komagome HospitalBunkyo Ku, JapanTaking people
- National Hospital Organization Osaka National HospitalOsaka, JapanTaking people
- Hokkaido University HospitalSapporo, JapanTaking people
- National Hospital Organization Sendai Medical CenterSendai, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kiminori Kimura, MD
- Trial code
- NCT07681089
- Record updated
- 5 October 2026
- Original description
This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.Read full original descriptionShow less
A Multicenter, Single-Arm, Open-Label Phase 2 Study of Once-Weekly Foscenvivint in Patients With Liver Cirrhosis Due to HIV/HCV Co-infection in the Setting of Hemophilia
This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.
Inclusion: Patients with hemophilia and liver cirrhosis caused by HIV/HCV co-infection who meet both of the following criteria:; Patients who are serum HIV-RNA positive or HIV antibody positive, with HIV-RNA maintained at <200 copies/mL and a CD4-positive T lymphocyte count of ≥200 cells/µL at screening; Patients with HCV infection who have achieved sustained virologic response (SVR) at least 12 months before registration; Patients with Child-Pugh class A or B liver cirrhosis (Child-Pugh score 5-9); Patients who meet at least one of the following criteria for the diagnosis of liver cirrhosis:; <!-- -->; Liver stiffness measurement by FibroScan of ≥12.5 kPa, corresponding to fibrosis stage F4, at screening; Abdominal CT showing changes in liver morphology and/or findings suggestive of portal hypertension; Patients with an Eastern Cooperative Oncology Group Performance Status of 0-2.
Exclusion: Patients who have undergone liver transplantation or other organ transplantation, including bone marrow transplantation; Patients with liver cirrhosis caused by etiologies other than HCV or of unknown etiology; Patients with current malignancy or a history of malignancy within 3 years before registration; Patients with active AIDS-defining disease requiring treatment. -; Patients with esophageal or gastric varices judged by endoscopic examination at screening to require treatment.